J&J Shows Grace Under Pressure From Biosimilars And Other Threats
Executive Summary
Oncology stars Darzalex and Imbruvica lift a strong fourth quarter, but Remicade biosimilars and pricing discounts continue to threaten to take a bite out of future performance. Tax reform and Amazon's potential entry into healthcare could also affect the diversified firm.
You may also be interested in...
Pfizer, Astellas Accelerate Xtandi's Timeline In Early Prostate Cancer
Protocol changes for the Phase III ARCHES and EMBARK trials will deliver results in hormone-sensitive prostate cancer a year and a half earlier than expected. Xtandi may then gain a valuable new indication sooner than anticipated, but generics for competitor Zytiga could launch before then.
How Is Pharma Spending Tax Savings? Not On Drug Pricing, Sen. Booker Says
As pharma invests its bounty from last year's tax reform in stock buybacks, capital improvements and other investments, Sen. Cory Booker issues a report suggesting companies should lower drug prices instead, but does not offer recommendations for how that might be done.
J&J Stays Within Price Pledge, But Average Doesn't Tell The Whole Story, Analyst Says
Bernstein analyst looks into J&J's average net price decline in 2017 and notes average sales price hikes for growth products Darzalex and Imbruvica are offset by price cuts for drugs facing competition. All products had single digit increases, though.